How many 8-K filings has Bolt Biotherapeutics, Inc. filed?

Bolt Biotherapeutics, Inc. (BOLT) has 10 8-K (Current Event Report) filings on record, spanning Jun 2024 to Oct 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Bolt Biotherapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Bolt Biotherapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Bolt Biotherapeutics, Inc. (BOLT) — 8-K Filings

All 8-K filings from Bolt Biotherapeutics, Inc.. Browse 10 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (10)

Bolt Biotherapeutics Reports Exit/Disposal Activities — Oct 2, 2025 Risk: medium
Bolt Biotherapeutics, Inc. filed an 8-K on October 2, 2025, reporting on cost associated with exit or disposal activities and other events as of October 1, 2025
Bolt Biotherapeutics Delisted from Nasdaq — Jun 6, 2025 Risk: high
Bolt Biotherapeutics, Inc. filed an 8-K on June 6, 2025, to report its delisting from the Nasdaq Capital Market due to failure to meet continued listing standar
Bolt Biotherapeutics, Inc. Files 8-K — Jun 4, 2025 Risk: low
On June 4, 2025, Bolt Biotherapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's former name from Bolt Therapeutics, Inc. to Bolt
Bolt Biotherapeutics Files 8-K on Security Holder Vote Matters — May 28, 2025 Risk: low
On May 27, 2025, Bolt Biotherapeutics, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated in D
Bolt Biotherapeutics Files 8-K for Bylaw Amendments — Apr 16, 2025 Risk: low
Bolt Biotherapeutics, Inc. filed an 8-K on April 15, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company
Bolt Biotherapeutics Faces Nasdaq Delisting Warning — Jan 3, 2025 Risk: high
Bolt Biotherapeutics, Inc. announced on January 2, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing r
Bolt Biotherapeutics Announces Board and Executive Changes — Dec 23, 2024 Risk: medium
On December 23, 2024, Bolt Biotherapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicate
Bolt Biotherapeutics Announces Executive and Board Changes — Sep 4, 2024 Risk: medium
On August 28, 2024, Bolt Biotherapeutics, Inc. announced changes to its board of directors and executive compensation. Specifically, Dr. David J. Earp was appoi
Bolt Biotherapeutics Faces Nasdaq Delisting — Jul 3, 2024 Risk: high
Bolt Biotherapeutics, Inc. filed an 8-K on July 3, 2024, to report that it has failed to meet the continued listing standards of the Nasdaq Stock Market. The co
Bolt Biotherapeutics Files 8-K on Security Holder Vote Matters — Jun 14, 2024 Risk: medium
On June 12, 2024, Bolt Biotherapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in D

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX